Weekly first-line chemotherapy of metastatic breast cancer with cyclophosphamide and epirubicin
| Autor: | Juan J. Breton, Esperanza Blanco, Antonio Garcia, Joaquin Belon, Enrique Aranda, Lorenzo Alonso, Roberto Lasso, Emilio Alba, Miguel Angel Sánchez-chaparro |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Adult
Cancer Research medicine.medical_specialty Time Factors Cyclophosphamide Nausea medicine.medical_treatment Breast Neoplasms Neutropenia Gastroenterology Drug Administration Schedule Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Aged Epirubicin Chemotherapy business.industry General Medicine Middle Aged medicine.disease Metastatic breast cancer Regimen Oncology Vomiting Female medicine.symptom business medicine.drug |
| Zdroj: | Scopus-Elsevier |
| ISSN: | 0300-8916 |
| Popis: | Forty-six patients with metastatic breast cancer who had not received previous chemotherapy for advanced disease entered a phase II trial of weekly chemotherapy with cyclophosphamide (250 mg/m2) + epirubicin (25 mg/m2) for 16 weeks. The overall response rate was 61 % (95 % confidence limits, 47-75 %), with 10 complete and 17 partial responses. Toxicity was mild and confined to nausea and vomiting and asymptomatic neutropenia (except in 2 cases). Sixty-three per cent of patients had no side effects. Weekly cyclophosphamide + epirubicin is an active and nontoxic regimen for patients with metastatic breast cancer who have had no prior anthracycline-containing adjuvant chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|